Xu Yang, Lan Fei, Bi Qiang, Li Xinyi, Wang Zhiyu, Li Ying, Li Pengfei, Long Haichen, Du Li
College of Medicine, Tarim University, Alar, 843300, Xinjiang, China.
Discov Oncol. 2025 May 23;16(1):884. doi: 10.1007/s12672-025-02675-0.
Ubiquitin-conjugating enzyme E2 C (UBE2C) is involved in tumor progression and cellular processes in many cancers and is implicated in cell cycle regulation. However, its prognostic significance in Hepatocellular carcinoma (HCC) and the mechanism of tumor immune response are unknown. The expression of UBE2C genes in HCC and normal tissue samples was investigated based on The Cancer Genome Atlas (TCGA) LIHC dataset and validated by Gene Expression Omnibus and Human Protein Atlas. Subsequently, the relationship between UBE2C gene expression, clinicopathologic parameters, and each survival period was investigated by regression analysis and Kaplan-Meier survival curves. The set of genes co-expressed with UBE2C was constructed and subjected to genomic enrichment analysis, GO and KEGG pathway enrichment analysis. Finally, the relationship between UBE2C gene expression and immune cell infiltration, immunosuppressive molecules in tumor samples from the TCGA-LIHC dataset was investigated. UBE2C gene expression levels were significantly higher in HCC samples compared to normal samples (p < 0.05). Higher UBE2C gene expression was closely associated with higher tumor grade and later tumor stage. The results of Kaplan-Meier survival curves showed that the survival of HCC patients with high UBE2C expression was shorter than that of patients with low UBE2C expression (p < 0.05, HR(CI) = 1.870[1.276, 2.741]). The results of PPI showed a high correlation between cell cycle-related proteins and UBE2C gene expression. Additionally, the highly expressed UBE2C gene was associated with an increased number of immunosuppressive molecules. UBE2C is an independent predictive marker for HCC patients, and the prognostic value of survival is improved when combined with clinical stage information. This study reveals its potential as a prognostic biomarker and as a new target for HCC intervention.
泛素结合酶E2 C(UBE2C)参与多种癌症的肿瘤进展和细胞进程,并与细胞周期调控有关。然而,其在肝细胞癌(HCC)中的预后意义以及肿瘤免疫反应机制尚不清楚。基于癌症基因组图谱(TCGA)的LIHC数据集研究了UBE2C基因在HCC和正常组织样本中的表达情况,并通过基因表达综合数据库和人类蛋白质图谱进行了验证。随后,通过回归分析和Kaplan-Meier生存曲线研究了UBE2C基因表达、临床病理参数与各生存期之间的关系。构建了与UBE2C共表达的基因集,并进行了基因组富集分析、GO和KEGG通路富集分析。最后,研究了TCGA-LIHC数据集中肿瘤样本中UBE2C基因表达与免疫细胞浸润、免疫抑制分子之间的关系。与正常样本相比,HCC样本中UBE2C基因表达水平显著更高(p<0.05)。UBE2C基因高表达与更高的肿瘤分级和更晚的肿瘤分期密切相关。Kaplan-Meier生存曲线结果显示,UBE2C高表达的HCC患者生存期短于UBE2C低表达患者(p<0.05,HR(CI)=1.870[1.276, 2.741])。蛋白质-蛋白质相互作用(PPI)结果显示细胞周期相关蛋白与UBE2C基因表达之间存在高度相关性。此外,UBE2C基因高表达与免疫抑制分子数量增加有关。UBE2C是HCC患者的独立预测标志物,结合临床分期信息可提高生存预后价值。本研究揭示了其作为预后生物标志物和HCC干预新靶点的潜力。